pegsitacianine

DRUG3 trials

Sponsors

OncoNano Medicine, Inc., University of Texas Southwestern Medical Center

Conditions

Head and Neck CancerHead and Neck Squamous Cell CarcinomaLung CancerPeritoneal CarcinomatosisUnknown Primary Cancer

Phase 2

A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets

CompletedNCT04950166

OncoNano Medicine, Inc.Peritoneal Carcinomatosis

Start: 2021-11-30End: 2023-01-20Updated: 2024-11-08

A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies

CompletedNCT05048082

OncoNano Medicine, Inc.Lung Cancer

Start: 2022-04-13End: 2022-08-31Updated: 2024-11-08

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

RecruitingNCT05576974

University of Texas Southwestern Medical CenterHead and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Unknown Primary Cancer

Start: 2024-04-17End: 2027-12-31Target: 120Updated: 2026-04-14

Related Papers

Bridging preclinical and clinical fluorescence-guided surgery with advanced cancer vision goggles

npj Imaging2026-05-25

Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study.

2024-04-157 citations

Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study.

Journal of Clinical Oncology2023-06-011 citations